Competition Intensifies As Access Increases For US Biosimilars
AmerisourceBergen’s Beth McMahon Also Highlights Ranibizumab And Adalimumab Rivals
Executive Summary
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.